The Experts below are selected from a list of 66 Experts worldwide ranked by ideXlab platform
Bruce D Weintraub - One of the best experts on this subject based on the ideXlab platform.
-
thyrotropin secreting pituitary tumors
Endocrine Reviews, 1996Co-Authors: Paolo Beckpeccoz, Francoise Bruckerdavis, Luca Persani, Robert C Smallridge, Bruce D WeintraubAbstract:I. Introduction The term “TSH-secreting pituitary tumors” includes two opposite clinical conditions: true thyrotroph neoplasia that results in secondary hyperthyroidism, also called “central hyperthyroidism,” and pituitary hyperplasia resulting from longstanding primary hypothyroidism. The latter condition was first recognized 145 yr ago (1), while the former was not clearly identified until the RIA era (2–8). However, in the 1950s and 1960s, while it became clear that Graves' disease was not caused by Hyperpituitarism (9, 10), scattered reports suggested a possible association between pituitary tumors and hyperthyroidism (11–15), although no measurement of TSH levels was available during this time. The first case of TSH-secreting pituitary adenoma (TSH-oma) was documented in 1960 by measuring serum TSH levels with a bioassay (16). In 1970, Hamilton et al. (17) reported the first case of TSH-oma proved by a RIA that was much more sensitive and specific than the previously used bioassays. Classically, TSH-...
Akio Morita - One of the best experts on this subject based on the ideXlab platform.
-
Pituitary surgery’s epidemiology using a national inpatient database in Japan
Acta Neurochirurgica, 2020Co-Authors: Yujiro Hattori, Shigeyuki Tahara, Hiroki Matsui, Kiyohide Fushimi, Hideo Yasunaga, Akio MoritaAbstract:Background Between 2010 and 2014, microscopic transsphenoidal surgery (mTSS) was performed more frequently than endoscopic TSS (eTSS) in the USA. However, few epidemiological studies on pituitary surgery are currently available. Methods We performed a retrospective study on patients who had undergone pituitary surgery between July 2010 and March 2016. To this end, a nationwide inpatient database in Japan was used. Patients’ characteristics, diagnoses, types of surgery, complications, and discharge status were examined. Results A total of 16,253 inpatients who received pituitary surgery were identified. Patients were diagnosed with diseases for insurance claims described below: pituitary adenoma, hyperprolactinemia, other pituitary disorders (e.g., Rathke’s cleft cyst), Hyperpituitarism, craniopharyngioma, acromegaly, Cushing’s disease, and pituitary cancer. Among them, pituitary adenomas, primarily the non-functioning ones, were the most frequent (66.9%). A total of 14,285 (88%) patients underwent TSS, while 1968 (12%) patients were treated using transcranial surgery. The number of patients undergoing TSS increased each year. The number of eTSS operations was 8140 (77%) and that of mTSS operations was 2419 (23%). Of note, eTSS increased each year. We found that high-volume hospitals more frequently selected eTSS. Compared with mTSS, eTSS was associated with a reduction of hyponatremia incidence (odds ratio, 0.69; p = 0.019). Additionally, it was not associated with other major complications. Conclusion The present study showed that both TSS and eTSS increased on a yearly basis. We believe that the present study will be the basis of future epidemiological investigations of pituitary surgery.
-
Pituitary surgery's epidemiology using a national inpatient database in Japan.
Acta neurochirurgica, 2020Co-Authors: Yujiro Hattori, Shigeyuki Tahara, Hiroki Matsui, Kiyohide Fushimi, Hideo Yasunaga, Shotaro Aso, Akio MoritaAbstract:Background Between 2010 and 2014, microscopic transsphenoidal surgery (mTSS) was performed more frequently than endoscopic TSS (eTSS) in the USA. However, few epidemiological studies on pituitary surgery are currently available. Methods We performed a retrospective study on patients who had undergone pituitary surgery between July 2010 and March 2016. To this end, a nationwide inpatient database in Japan was used. Patients' characteristics, diagnoses, types of surgery, complications, and discharge status were examined. Results A total of 16,253 inpatients who received pituitary surgery were identified. Patients were diagnosed with diseases for insurance claims described below: pituitary adenoma, hyperprolactinemia, other pituitary disorders (e.g., Rathke's cleft cyst), Hyperpituitarism, craniopharyngioma, acromegaly, Cushing's disease, and pituitary cancer. Among them, pituitary adenomas, primarily the non-functioning ones, were the most frequent (66.9%). A total of 14,285 (88%) patients underwent TSS, while 1968 (12%) patients were treated using transcranial surgery. The number of patients undergoing TSS increased each year. The number of eTSS operations was 8140 (77%) and that of mTSS operations was 2419 (23%). Of note, eTSS increased each year. We found that high-volume hospitals more frequently selected eTSS. Compared with mTSS, eTSS was associated with a reduction of hyponatremia incidence (odds ratio, 0.69; p = 0.019). Additionally, it was not associated with other major complications. Conclusion The present study showed that both TSS and eTSS increased on a yearly basis. We believe that the present study will be the basis of future epidemiological investigations of pituitary surgery.
Paolo Beckpeccoz - One of the best experts on this subject based on the ideXlab platform.
-
thyrotropin secreting pituitary tumors
Endocrine Reviews, 1996Co-Authors: Paolo Beckpeccoz, Francoise Bruckerdavis, Luca Persani, Robert C Smallridge, Bruce D WeintraubAbstract:I. Introduction The term “TSH-secreting pituitary tumors” includes two opposite clinical conditions: true thyrotroph neoplasia that results in secondary hyperthyroidism, also called “central hyperthyroidism,” and pituitary hyperplasia resulting from longstanding primary hypothyroidism. The latter condition was first recognized 145 yr ago (1), while the former was not clearly identified until the RIA era (2–8). However, in the 1950s and 1960s, while it became clear that Graves' disease was not caused by Hyperpituitarism (9, 10), scattered reports suggested a possible association between pituitary tumors and hyperthyroidism (11–15), although no measurement of TSH levels was available during this time. The first case of TSH-secreting pituitary adenoma (TSH-oma) was documented in 1960 by measuring serum TSH levels with a bioassay (16). In 1970, Hamilton et al. (17) reported the first case of TSH-oma proved by a RIA that was much more sensitive and specific than the previously used bioassays. Classically, TSH-...
Robert C Smallridge - One of the best experts on this subject based on the ideXlab platform.
-
thyrotropin secreting pituitary tumors
Endocrine Reviews, 1996Co-Authors: Paolo Beckpeccoz, Francoise Bruckerdavis, Luca Persani, Robert C Smallridge, Bruce D WeintraubAbstract:I. Introduction The term “TSH-secreting pituitary tumors” includes two opposite clinical conditions: true thyrotroph neoplasia that results in secondary hyperthyroidism, also called “central hyperthyroidism,” and pituitary hyperplasia resulting from longstanding primary hypothyroidism. The latter condition was first recognized 145 yr ago (1), while the former was not clearly identified until the RIA era (2–8). However, in the 1950s and 1960s, while it became clear that Graves' disease was not caused by Hyperpituitarism (9, 10), scattered reports suggested a possible association between pituitary tumors and hyperthyroidism (11–15), although no measurement of TSH levels was available during this time. The first case of TSH-secreting pituitary adenoma (TSH-oma) was documented in 1960 by measuring serum TSH levels with a bioassay (16). In 1970, Hamilton et al. (17) reported the first case of TSH-oma proved by a RIA that was much more sensitive and specific than the previously used bioassays. Classically, TSH-...
Luca Persani - One of the best experts on this subject based on the ideXlab platform.
-
thyrotropin secreting pituitary tumors
Endocrine Reviews, 1996Co-Authors: Paolo Beckpeccoz, Francoise Bruckerdavis, Luca Persani, Robert C Smallridge, Bruce D WeintraubAbstract:I. Introduction The term “TSH-secreting pituitary tumors” includes two opposite clinical conditions: true thyrotroph neoplasia that results in secondary hyperthyroidism, also called “central hyperthyroidism,” and pituitary hyperplasia resulting from longstanding primary hypothyroidism. The latter condition was first recognized 145 yr ago (1), while the former was not clearly identified until the RIA era (2–8). However, in the 1950s and 1960s, while it became clear that Graves' disease was not caused by Hyperpituitarism (9, 10), scattered reports suggested a possible association between pituitary tumors and hyperthyroidism (11–15), although no measurement of TSH levels was available during this time. The first case of TSH-secreting pituitary adenoma (TSH-oma) was documented in 1960 by measuring serum TSH levels with a bioassay (16). In 1970, Hamilton et al. (17) reported the first case of TSH-oma proved by a RIA that was much more sensitive and specific than the previously used bioassays. Classically, TSH-...